CHEMFABBSEChemfab Alkalis LtdHighNeutral
Announced Wed, 13 May · 21:14 IST

The Board meeting held today i.e., 13th May, 2026 has approved the Audited Standalone and Consolidated Financial Results for the quarter and year ended 31st March, 2026 as recommended by ....

Revenue DeclinePat NegativeExceptional ItemEbitda Margin CompressionResults View source PDF

CHEMFAB · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close
-2.8%1-day move
₹436.00
prior close
₹426.40
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
+1.4+0.9+0.8-0.6-2.8-2.5-6.0-6.9-5.0-5.3-3.7-12.8-14.0
Up moveDown movePending
AI summary

Chemfab Alkalis reported audited standalone FY2026 results with revenue from operations declining to Rs. 28,857 Lakhs from Rs. 32,209 Lakhs in FY2025. Net profit dropped significantly to Rs. 751 Lakhs from Rs. 1,522 Lakhs (approximately 51% decline), with EPS falling to Rs. 5.22 from Rs. 10.65. On consolidated basis, the company reported a net loss of Rs. 343 Lakhs (improved from loss of Rs. 694 Lakhs in FY2025), though this includes an exceptional item of Rs. 989 Lakhs. The board recommended a final dividend of Rs. 1.25 per share (12.50%) subject to shareholder approval. Statutory auditor Deloitte Haskins & Sells LLP issued an unmodified opinion, and new internal auditors Brahmayya & Co and cost auditors Madhavan, Mohan & Associates were appointed for FY2027.

Likely market impact

The significant decline in standalone profitability despite positive operating cash flows of Rs. 4,094 Lakhs may concern investors. The reduction in consolidated net loss and clean audit opinion are positives, but the revenue contraction and earnings decline suggest operational headwinds in the chemicals segment.